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Background: This was a prospective observational study designed to evaluate direct and 
indirect costs and quality of life for patients with Crohn’s disease in Italy from the perspectives 
of the National Health System and of society.
Methods: A total of 162 male and female subjects aged 18–70 years with Crohn’s disease in 
the active phase and a Crohn’s Disease Activity Index score $150 were included in the study. 
Subjects were recruited from 25 Italian centers on a consecutive basis. The study consisted of 
four visits undertaken every 6 months with a follow-up period of 18 months. The study started 
on September 1, 2006 and was completed on April 12, 2010. Multivariate analyses were carried 
out on demographic characteristics, treatment costs based on the prescribed daily dose, resource 
use and other cost parameters, and changes in quality of life using the EQ5D questionnaire.
Results: Cost of illness per subject with Crohn’s disease in Italy was estimated to be €15,521 
per year, with direct costs representing 76% of total costs. Nonhealth care costs and loss of 
productivity accounted for 24% of total costs. Societal costs during the first months of enrolment 
were higher compared with costs in the final months of the study. Quality of life measured by 
the EQ-5D was 0.558 initially and then increased to 0.739, with a mean value of 0.677 during 
the enrolment period. The cost of illness was not correlated with age or gender.
Conclusion: The cost of illness was correlated with quality of life; Crohn’s disease had a 
negative impact on subjects’ quality of life, and higher costs corresponded to a lower quality 
of life as measured with the EQ5D. Drug treatment may improve quality of life and reduce 
hospitalization costs. Our results appear to be in line with the results of other international 
cost-of-illness studies.
Keywords: Crohn’s disease, quality of life, EuroQol, EQ5D, cost-of-illness, cost analysis, 
economic evaluation
Introduction
Crohn’s disease is a chronic inflammatory condition that can involve any region of the 
gastrointestinal tract, from mouth to anus, but typically affects the distal small bowel, 
the terminal ileum (ileitis), and/or colon (colitis), or both (ileocolitis). Crohn’s disease 
is reasonably common, affecting about 100,000 Italians and 2 million Americans. The 
annual incidence is around 3–4 new cases per 100,000. The peak age of disease onset 
is 20–25 years, but the disease can manifest itself at any age, from infancy to over 
70 years of age, and affects males and females equally. Although the precise etiology 
of Crohn’s disease is still unknown, it is thought that the disease is related to a rich 
diet in developed countries or to specific genetic characteristics.1 Smoking and oral 
contraceptives are possible risk factors. Some studies have shown that the disease may 
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have a hereditary component, in that 15%–20% of individuals 
with Crohn’s disease have one or more close relatives with 
either Crohn’s disease or ulcerative colitis. The diagnosis can 
be difficult to make because symptoms of Crohn’s disease 
are similar to those of inflammatory bowel disease.2,3 Useful 
diagnostic tools are colonoscopy2,4 with biopsy, scintigraphy, 
and abdominal echography. More complex examinations, 
such as computerized axial tomography and nuclear magnetic 
resonance, are needed in the event of complications. The most 
common diagnostic symptom is abdominal pain associated 
with diarrhea and, sometimes, fever. Pain is localized to the 
umbilicus on the right side of the abdomen and often mani-
fests after meals. Other symptoms depend on location of the 
disease, and include inflammation around the anus and/or the 
perianal region; this localization is rather frequent, and leads 
to various complications like fistulae (abnormal connections 
between the intestine and the skin surface, by the anus) or 
abscesses. Complications associated with Crohn’s disease 
affect approximately 10%–20% of individuals, whereas the 
remaining 80%–90% respond successfully to treatment. 
Complications may be intestinal (stenoses, perforations, 
abdominal abscesses and fistulae, and carcinoma of the small 
bowel or colon) or systemic in that they can affect extraintes-
tinal sites leading to inflammation of the joints (eg, arthritis, 
arthralgia) eye inflammation (uveitis), skin conditions, kidney 
stones, gallstones, and nutritional problems (protein/vitamin 
deficiency,5 asthenia, anorexia, and weight loss).
All medical conditions have negative consequences for 
the patient, their family, and society. The patient experiences 
pain and suffering (with consequences on quality of life), 
has a shorter life expectancy, and increased expenses.6 
Families have to cope with emotional stress and financial 
loss. Society deals with the emotional burden on the family 
caused by the disease, in addition to providing for the cost 
of resource utilization for health care interventions and loss 
of productivity due to morbidity, disability, and premature 
death.7 Evaluation of total direct, indirect, and intangible 
costs of a disease is known as a cost-of-illness analysis. Such 
studies measure and evaluate the resources used to manage 
a disease and quantify the associated costs, thus serving 
as a tool for assessing the economic consequences of a 
condition on the economic system.8 Direct costs refer to the 
resources used to prevent and treat a disease, and associated 
issues such as medications, physicians, nursing personnel, 
laboratory monitoring, hospitalizations, and medical devices, 
as well as the costs of transportation to or from the hospital, 
special diets, and clothing. Indirect costs are due to loss of 
productivity of the patient or their caregivers because of the 
disease (eg, following hospitalization or because of visits). 
Intangible costs derive from the effects of the disease on 
patient and/or caregiver quality of life. The literature9–13 
suggests that the annual cost of Crohn’s disease is mainly 
due to hospitalizations, whereas medications account for 
only 7%–10% of the total annual cost for treating patients. 
Furthermore, the condition has a strong impact on quality of 
life. It is estimated that the total annual direct cost of Crohn’s 
disease in the United States is 1–1.2 billion dollars.13–15 
Individuals with Crohn’s disease experience considerable 
chronic morbidity and require important interventions. When 
this study was set up, knowledge about the direct, indirect, 
and intangible costs associated with Crohn’s disease was 
incomplete and scanty, especially in Italy. Our aim was to 
evaluate resource consumption due to Crohn’s disease in Italy 
and the effects of this condition on quality of life.
Materials and methods
Design
This was an observational prospective study designed by the 
COSMO Study Group to evaluate direct and indirect costs and 
quality of life in patients with Crohn’s disease in Italy from 
the perspectives of the National Health System and society. 
The primary objective of this study was to evaluate the cost of 
illness and quality of life of individuals with Crohn’s disease 
in the active phase and with a Crohn’s Disease Activity Index 
(CDAI) score $150 despite pharmacologic treatment, or with 
active fistulating disease, diagnosed at least 6 months earlier, 
and confirmed by x-rays, endoscopy, or other diagnostic 
examination. The key secondary study objectives were to 
give an indication of the various cost components paid by the 
National Health System and society for the management of 
individuals with Crohn’s disease and to provide an indication 
of the likely quality of life changes for individuals with Crohn’s 
disease relative to the different pharmacologic treatments.
Recruitment
The study consisted of four visits made every 6 months 
during a follow-up period of 18 months. It was anticipated 
that approximately 25 centers would enroll approximately 
10–40 subjects each on a consecutive basis. The study started on 
September 1, 2006 and was completed on April 12, 2010. The 
target number of subjects who would be eligible for enrolment 
into this study was about 245. A total of 162 subjects (67%) 
completed the study, while 83 subjects (33%) discontinued 
early. Reasons for discontinuation were: subject did not wish 
to continue (n = 55); loss to follow-up (n = 2); failure to return 
for follow-up visits (n = 18); serious adverse events (n = 3); 
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Table 2 Health care resource use per patient by observation period and type of resource used
Enrolment 6 months 12 months 18 months 
(n = 162) (min–max)  
(SD)
(n = 154) (min–max)  
(SD)
(n = 154) (min–max)  
(SD)
(n = 155) (min–max)  
(SD)
Number of
 Physician visits 5.0 (0–30) (6.24) 3.5 (0–30) (5.18) 3.1 (0–30) (4.44) 2.6 (0–25) (3.45)
 Specialist visits 3.4 (0–16) (2.70) 2.2 (0–15) (2.62) 2.2 (0–15) (2.47) 2.3 (0–10) (2.24)
 Diagnostic examinations 1.93 (0–12) (2.10) 0.78 (0–5) (1.10) 0.73 (0–6) (1.14) 0.68 (0–5) (1.13)
 Laboratory tests 0.97 (0–1) (0.174) 0.96 (0–1) (0.194) 0.94 (0–1) (0.235) 0.99 (0–1) (0.234)
 Emergency room 0.93 (0–19) (2.29) 0.11 (0–6) (0.662) 0.21 (0–8) (0.975) 0.12 (0–6) (0.693)
Abbreviation: SD, standard deviation.
other medical event (n = 29); and unspecified reasons (n = 3). 
Subjects who withdrew from the study prematurely were not 
included in the pharmacoeconomic analysis.
All prior medication taken by the subject within 6 months 
of starting the study and all concomitant therapy taken during 
the study were recorded on the case report form. The identity 
of the therapy, the dose, route, and regimen, the dates started 
and stopped (or notation of “continuing” if that was the case), 
and the reason for use were recorded. The study was approved 
by the relevant local ethical committees, and Declaration of 
Helsinki protocols were followed. Written informed consent 
was obtained from all participants.
Inclusion and exclusion criteria
A subject was eligible for participation in the study based on 
the following inclusion criteria:
•	 Age 18–70 years
•	 Crohn’s disease in the active phase with a CDAI score 
$150 despite pharmacologic treatment, or with active 
fistulating disease
•	 Crohn’s disease diagnosed within at least 6 months of 
study entry and confirmed by x-rays, endoscopy, or other 
diagnostic examination
•	 Provision of informed consent
•	 Ability to understand the aims of the study and to answer 
all items on the questionnaire.
A subject was excluded from participation in the study 
based on the following exclusion criteria:
•	 Unreliability as to questionnaire completion, eg, past or 
current abuse of drugs or alcohol, or serious concomitant 
neurologic and/or psychiatric conditions
•	 Concomitant diseases that may interfere with the costs of 
Crohn’s disease or its complications, including serious 
infections (eg, tuberculosis in the active phase), organ 
transplantation, malignancy, human immunodeficiency 
virus infection, or uncontrolled renal, cardiac, hepatic, 
or endocrine disease
•	 Subjects currently enrolled in another clinical study.
Direct costs
Direct health care costs were related to physician visits, 
specialist visits, drug treatment and infusions, diagnostic 
examinations, laboratory tests, emergency room attendances, 
and hospitalization.16 Hospitalization costs were evaluated 
on the basis of the national DRG system available from the 
Italian Ministry of Health.17 Specialist medical examinations, 
laboratory tests, diagnostic procedures, and phototherapy 
sessions were based on the 2010 National Tariff Nomenclator.18 
Health care services provided by the private sector and 
other private costs were evaluated according to the actual 
expenses incurred by patients. All pharmacologic therapies 
(topical, systemic, biologics, multiple) were considered in the 
questionnaire. Alternative treatments were also assessed. To 
assess the costs of prescribed pharmacologic therapies, units 
of consumed resources were multiplied by the prices reported 
in the official Italian price list,19 taking into consideration the 
dosage and duration of treatment. The costs of nonprescription 
topical medications and alternative treatments were 
determined by averaging the costs of the most representative 
drugs recorded in the patient notebooks, based on the official 
retail price list. Nonhealth care costs related to transport of 
patients and their relatives, home assistance by volunteers 
or relatives, and home assistance by others were evaluated 
according to the actual expenses incurred by patients.
Indirect costs
The human capital approach was used to estimate productivity 
loss due to Crohn’s disease.8,16 Travel costs were not collected. 
Indirect costs included the value of lost production due to 
leaving work earlier than usual, sick leave, and loss of leisure 
time for nonemployees during the study. Patients’ time off 
work (lost working days, permanent reduction or loss of work 
activities) was measured in terms of salary evaluation, with the 
assumption that income reflects productivity. The monetary 
value of one lost working day for patients was calculated to 
be €98.44, equal to the gross domestic product per capita 
per day.20 National income data were subsequently updated 
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Enrolment 6 months 12 months 18 months Total on 24
months
Costs for productivity lossNon-health care costsHeart care direct costs
Figure 1 Cost (Euro) per patient by observation period and type of resource used.
to 2011 according to official inflation rates, and represented 
a mean value for all of Italy. The analysis was done from 
both societal and National Health Service perspectives. All 
costs are expressed in Euros and were updated to 2011 values 
according to official inflation rates.21
Quality of life
In order to assess quality of life in its broadest sense, 
patients were asked to complete the EuroQoL22 questionnaire 
(EQ-5D™) which is a standardized instrument for use as 
a measure of health outcome. Applicable to a wide range 
of health conditions and treatments, it provides a simple 
descriptive profile and a single index value for health status.23 
The EQ-5D questionnaire considers five attributes of quality 
of life evaluation, ie, mobility, self-care, usual activity, pain/
discomfort, and anxiety/depression.24–26 Each attribute has 
three levels, ie, no problems, some problems, or major 
problems, thus defining 243 possible health states, to which 
has been added “unconscious” and “dead”, for a total of 
245. The scores fall on the 0.0 (dead) to 1.0 (perfect health) 
value scale.26,27
Statistical analysis
All variables were analyzed using descriptive statistics, ie, 
mean, standard deviation, median, maximum, and minimum 
values for continuous variables, and frequency distribution 
for categorical variables. Results are reported as a whole 
and separately for each gender and age group. Specifically, 
variables considered were demographic characteristics, 
resource use, other cost parameters, and changes in qual-
ity of life.16 The economic analysis was based on the 
subjects who completed the 18-month follow-up period 
in this study.
Results
Table 1 shows the main sociodemographic and quality of 
life characteristics. The mean age of the 162 patients (50% 
males) was 43 years. At recruitment, the EuroQol score was 
0.558, as shown in Table 1. Treatment patterns at baseline 
(enrolment) and during the observation period are shown 
in Table 2. Health care resource consumption per patient 
declined during the observation period.
The consumption of medical services and medication 
at enrolment and during the period of observation is shown 
in Table 3 and Figure 1. The mean total cost (direct and 
indirect) per patient was €31,043.40 during the 24 months 
of observation. Direct costs accounted for 76.3% of the 
total estimated disease costs for Crohn’s disease. The 
most significant direct costs pertained to drug treatment 
(60.3%) followed by hospitalization (10.9%) and laboratory 
examinations (2.6%). Other components of direct cost had 
a marginal impact on direct costs. Costs related to loss of 
productivity amounted to €5567.80, accounting for 17.9% 
of total costs (Figure 1).
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The total cost was higher for males (Table 4), with the 
cost difference between males and females being mainly 
due to indirect costs, although the difference (+3%) was not 
statistically significant. We did not find any cost difference 
according to age group. Societal costs during the first period 
of the study were higher compared with costs in the last 
period of the study (Tables 3 and 4).
Quality of life as measured with the EQ-5D was initially 
0.558, and then increased to 0.739, with a mean value of 
0.677 during the study (Table 1). However, cost seemed to be 
strongly correlated with decreased quality of life (Table 5); 
the mean health care and societal costs for subjects with 
a quality of life of 0–0.499 was €6179 higher than that of 
subjects with a quality of life of 0.50–1.00. Expenses incurred 
for Crohn’s disease treatment were significantly higher for 
patients with poorer quality of life than for patients with 
better quality of life (Table 5). Therefore, an increase in drug 
treatment improved quality of life and markedly reduced 
hospitalization costs.
Discussion
Crohn’s disease may have a profound impact on an affected 
person’s quality of life and a substantial economic impact 
for both patients and the health care system.28 In spite of this, 
only a few studies have presented an overall picture of the 
costs of care for patients with Crohn’s disease.9–12,28 This also 
applies to Italy, where little is known about the epidemiology 
or economics of Crohn’s disease. This national multicenter 
prospective study on the cost of Crohn’s disease in Italy was 
performed using a bottom-up approach in patients during 
the active phase of the illness with a CDAI score $150. 
Evaluation of the total direct, indirect, and intangible costs 
of a disease is known as cost-of-illness analysis. Such studies 
measure and evaluate the resources used to manage a disease 
and quantify the associated costs, thus serving as a tool for 
assessing the economic consequences of a disease.
The burden of Crohn’s disease per subject in Italy was 
assessed to be approximately €11,838 (including only 
direct costs) to €15,521 per year (including direct cost and 
productivity loss). Direct costs represented 76% of the total 
costs, and nonhealth care costs and productivity loss accounted 
for 24%. We did not find differences in cost between males 
and females or according to age group. Patients over 65 years 
comprised only 12% of the total sample, which has a mean 
age of 43 years. Loss of production was calculated overall 
for patients who were still working in active employment. 
Societal costs during the early months of the study were higher 
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Table 5 Cost (Euro) per patient by EuroQoL score and type of resource used 
Enrolment 6 months 12 months 18 months
,0 
(n = 14)
0 to  
0.499 
(n = 29)
0.500 to  
0.749 
(n = 77)
0.750 to  
0.899 
(n = 33)





0 to  
0.499 
(n =18)
0.500 to  
0.749 
(n = 65)








0 to  
0.499 
(n = 15)
0.500 to  
0.749 
(n = 61)
0.750 to  
0.899 
(n	= 35)





0 to  
0.499 
(n = 14)
0.500 to  
0.749 
(n = 54)






Health care direct costs 6,856.9 7,130.9 6,265.0 4,611.4 5,460.4 9,417.4 8,322.9 6,875.7 4,946.4 4,587.1 6,854.0 7,151.1 6,589.6 4,555.9 4,207.5 5,222.2 7,389.1 6,139.6 5,987.3 4,988.8
Physician visits 74.0 71.4 45.9 63.8 28.8 45.0 40.0 48.7 25.7 32.5 33.8 64.6 39.1 33.5 18.1 42.2 40.2 33.2 31.9 17.5
Specialist visits 148.3 89.6 84.3 84.9 32.1 67.1 49.2 54.5 40.7 56.4 68.9 59.0 54.7 40.7 36.3 67.1 58.3 57.6 50.5 35.3
Drug treatment  
and drug infusion
3,962.4 4,503.3 3,963.9 2,939.4 4,793.8 9,036.9 6,648.6 5,583.3 4,220.4 3,362.8 5,562.6 6,264.6 5,518.0 3,770.3 3,804.2 4,114.4 5,395.4 5,280.9 5,505.0 4,525.1
Diagnostic examinations 178.9 171.2 139.2 156.1 29.6 69.7 57.2 71.0 42.8 60.1 128.4 135.6 62.4 32.6 21.4 83.9 103.4 73.4 41.1 33.0
Laboratory tests 418.4 323.1 245.8 218.2 258.4 152.2 147.7 195.6 177.3 180.3 253.6 223.0 195.9 208.3 117.5 163.0 227.6 182.3 184.2 147.2
Emergency room 86.3 47.0 19.7 15.0 0.0 46.5 6.9 3.3 0.0 0.0 0.0 8.3 10.2 7.1 0.0 46.5 17.7 0.0 3.4 0.0
Hospitalizations 1,988.6 1,925.2 1,766.1 1,133.9 317.8 0.0 1,373.3 919.2 439.5 895.0 806.7 396.0 709.3 463.4 210.0 705.0 1,546.4 512.2 171.1 230.6
Non-health care costs 3,983.6 1,373.2 920.5 404.0 185.9 4,970.6 616.5 213.2 147.0 102.8 12.7 263.0 147.3 151.9 94.6 623.9 204.6 164.9 175.9 130.3
Patient’s or relatives’  
transport
1,008.5 200.2 212.1 177.7 185.9 12.1 73.3 156.9 147.0 97.0 12.7 241.2 114.5 115.7 92.2 11.9 72.4 145.9 152.1 130.3
Home assistance by  
volunteers or relatives
2,885.1 1,141.0 672.4 220.9 0.0 4,896.0 543.2 56.3 0.0 0.0 0.0 21.8 32.8 36.1 0.0 612.0 116.6 17.4 23.8 0.0
Home assistance by others 85.7 16.6 27.3 0.0 0.0 25.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.4 0.0 15.7 0.0 0.0 0.0
Home nursing assistance by 
others
4.3 15.5 8.8 5.5 0.0 37.5 0.0 0.0 0.0 5.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.7 0.0 0.0
Costs for productivity loss 4,975.4 2,684.6 1,777.3 1,784.3 556.5 4,233.4 1,777.0 1,122.4 1,267.7 1,858.0 5,464.3 906.1 1,650.9 1,200.7 303.9 157.2 2,485.2 804.7 535.1 346.7
Total productivity loss 4,489.6 2,347.7 1,601.8 1,509.5 457.0 4,158.8 1,545.8 959.7 1,167.5 1,586.7 5,464.3 801.7 1,503.4 1,090.7 259.1 157.2 2,340.3 693.9 450.1 277.0
Relatives’ time loss 485.8 336.9 175.5 274.8 99.4 74.6 231.2 162.7 100.3 271.4 0.0 104.4 147.5 110.0 44.7 0.0 144.9 110.8 84.9 69.7
Total costs 15,816.0 11,188.8 8,962.8 6,799.7 6,202.8 18,621.4 10,716.5 8,211.3 6,361.1 6,548.0 12,330.9 8,320.1 8,387.8 5,908.4 4,606.0 6,003.4 10,079.0 7,109.2 6,698.3 5,465.8
Quality of life as measured by the EQ-5D was 0.558 ini-
tially, increasing to 0.739, with a mean value of 0.677 
during the study. Drug treatment was the most important 
cost item (60%), followed by the cost of hospitalization 
(10%).  However, cost seemed to be strongly correlated 
with diminished quality of life; at enrolment, the health 
care and societal costs for subjects with a quality of life 
of 0–0.499 was 84% higher than that for subjects with a 
quality of life of 0.50–1.00. It should be pointed out that 
drugs were the most significant item contributing to total 
cost, with drug costs increasing in proportion to decreas-
ing quality of life and decreasing costs of hospitalization. 
This relationship could be considered from another point 
of view, ie, treatment ameliorates the disease but at the 
cost of side effects which worsen quality of life. However, 
further research is needed to identify the exact reasons for 
this association.
The results of this study provide descriptive data on 
patterns of resource use and show that the more severe the 
Crohn’s disease, the higher the direct and indirect costs of 
its management, and that the direct costs are higher than 
the indirect costs. Quality of life in Crohn’s disease is poor 
when compared with that of the general population and for 
certain other common chronic diseases, eg, diabetes, in 
the Italian scenario.29 Our results appear to be in line with 
those of the international cost-of-illness studies performed 
in other countries.9–12,28
There are some limitations to this study and the results 
are likely to underestimate total disease costs for various rea-
sons. The first possible limitation concerns extrapolation of 
6-months expenses among the whole period of the study (18 
months), because patients’ expenses, especially in those with 
severe disease, are related both to the contextual conditions 
and to the commonly and routinely used items, whose costs 
can be underestimate in a short period of analysis. Use of the 
human capital approach to calculate indirect costs in the form 
of overall productivity losses can discriminate against people 
with no market value, such as the unemployed, retired people, 
and housewives. On the other side, this study included a com-
plete evaluation of comorbidities and reduction of productivity 
by families and caregivers. These expenses might represent an 
important cost driver for the total burden of disease.12,28
Increasing use of innovative treatments for Crohn’s disease 
has been noted recently, and with the advent of new biologic 
agents (infliximab, adalimumab, certolizumab), the costs of 
treating Crohn’s disease will be even higher.30,31 However, 
prescribing these new albeit costly drugs could be associated 
with less loss of productivity and a reduction in diagnostic 
procedures and hospitalization, with great benefit from the 
societal point of view.32 These investments in innovative 
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Table 5 Cost (Euro) per patient by EuroQoL score and type of resource used 
Enrolment 6 months 12 months 18 months
,0 
(n = 14)
0 to  
0.499 
(n = 29)
0.500 to  
0.749 
(n = 77)
0.750 to  
0.899 
(n = 33)





0 to  
0.499 
(n =18)
0.500 to  
0.749 
(n = 65)








0 to  
0.499 
(n = 15)
0.500 to  
0.749 
(n = 61)
0.750 to  
0.899 
(n	= 35)





0 to  
0.499 
(n = 14)
0.500 to  
0.749 
(n = 54)






Health care direct costs 6,856.9 7,130.9 6,265.0 4,611.4 5,460.4 9,417.4 8,322.9 6,875.7 4,946.4 4,587.1 6,854.0 7,151.1 6,589.6 4,555.9 4,207.5 5,222.2 7,389.1 6,139.6 5,987.3 4,988.8
Physician visits 74.0 71.4 45.9 63.8 28.8 45.0 40.0 48.7 25.7 32.5 33.8 64.6 39.1 33.5 18.1 42.2 40.2 33.2 31.9 17.5
Specialist visits 148.3 89.6 84.3 84.9 32.1 67.1 49.2 54.5 40.7 56.4 68.9 59.0 54.7 40.7 36.3 67.1 58.3 57.6 50.5 35.3
Drug treatment  
and drug infusion
3,962.4 4,503.3 3,963.9 2,939.4 4,793.8 9,036.9 6,648.6 5,583.3 4,220.4 3,362.8 5,562.6 6,264.6 5,518.0 3,770.3 3,804.2 4,114.4 5,395.4 5,280.9 5,505.0 4,525.1
Diagnostic examinations 178.9 171.2 139.2 156.1 29.6 69.7 57.2 71.0 42.8 60.1 128.4 135.6 62.4 32.6 21.4 83.9 103.4 73.4 41.1 33.0
Laboratory tests 418.4 323.1 245.8 218.2 258.4 152.2 147.7 195.6 177.3 180.3 253.6 223.0 195.9 208.3 117.5 163.0 227.6 182.3 184.2 147.2
Emergency room 86.3 47.0 19.7 15.0 0.0 46.5 6.9 3.3 0.0 0.0 0.0 8.3 10.2 7.1 0.0 46.5 17.7 0.0 3.4 0.0
Hospitalizations 1,988.6 1,925.2 1,766.1 1,133.9 317.8 0.0 1,373.3 919.2 439.5 895.0 806.7 396.0 709.3 463.4 210.0 705.0 1,546.4 512.2 171.1 230.6
Non-health care costs 3,983.6 1,373.2 920.5 404.0 185.9 4,970.6 616.5 213.2 147.0 102.8 12.7 263.0 147.3 151.9 94.6 623.9 204.6 164.9 175.9 130.3
Patient’s or relatives’  
transport
1,008.5 200.2 212.1 177.7 185.9 12.1 73.3 156.9 147.0 97.0 12.7 241.2 114.5 115.7 92.2 11.9 72.4 145.9 152.1 130.3
Home assistance by  
volunteers or relatives
2,885.1 1,141.0 672.4 220.9 0.0 4,896.0 543.2 56.3 0.0 0.0 0.0 21.8 32.8 36.1 0.0 612.0 116.6 17.4 23.8 0.0
Home assistance by others 85.7 16.6 27.3 0.0 0.0 25.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 2.4 0.0 15.7 0.0 0.0 0.0
Home nursing assistance by 
others
4.3 15.5 8.8 5.5 0.0 37.5 0.0 0.0 0.0 5.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.7 0.0 0.0
Costs for productivity loss 4,975.4 2,684.6 1,777.3 1,784.3 556.5 4,233.4 1,777.0 1,122.4 1,267.7 1,858.0 5,464.3 906.1 1,650.9 1,200.7 303.9 157.2 2,485.2 804.7 535.1 346.7
Total productivity loss 4,489.6 2,347.7 1,601.8 1,509.5 457.0 4,158.8 1,545.8 959.7 1,167.5 1,586.7 5,464.3 801.7 1,503.4 1,090.7 259.1 157.2 2,340.3 693.9 450.1 277.0
Relatives’ time loss 485.8 336.9 175.5 274.8 99.4 74.6 231.2 162.7 100.3 271.4 0.0 104.4 147.5 110.0 44.7 0.0 144.9 110.8 84.9 69.7
Total costs 15,816.0 11,188.8 8,962.8 6,799.7 6,202.8 18,621.4 10,716.5 8,211.3 6,361.1 6,548.0 12,330.9 8,320.1 8,387.8 5,908.4 4,606.0 6,003.4 10,079.0 7,109.2 6,698.3 5,465.8
treatments for Crohn’s disease might also  provide future 
benefits, due to avoidance of recurrent problems, improved 
compliance, and better quality of life.33,34 Adequate analysis 
of outcomes and costs, as performed for the biologics in 
current use, should be assessed in terms of their incremental 
cost-effectiveness ratio.35
In conclusion, this project is the first complete study of 
the burden of Crohn’s disease in Italy. Crohn’s disease is an 
important economic burden in Italy, both to society and the 
National Health System.36 This study provides evidence of 
an association between severity of Crohn’s disease and cost 
of illness, as well as basic data for further decision-making, 
dealing especially with economic assessment of innovative 
therapies for moderate and severe plaque psoriasis. Further 
data on outcomes need to be collected over a longer 
time frame.
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